Consensus guidelines for antifungal stewardship, surveillance and infection prevention, 2021

Invasive fungal diseases (IFD) are serious infections associated with high mortality, particularly in immunocompromised patients. The prescribing of antifungal agents to prevent and treat IFD is associated with substantial economic burden on the health system, high rates of adverse drug reactions, s...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Internal medicine journal 2021-11, Vol.51 (S7), p.18-36
Hauptverfasser: Khanina, Anna, Tio, Shio Yen, Ananda‐Rajah, Michelle R., Kidd, Sarah E., Williams, Eloise, Chee, Lynette, Urbancic, Karen, Thursky, Karin A.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 36
container_issue S7
container_start_page 18
container_title Internal medicine journal
container_volume 51
creator Khanina, Anna
Tio, Shio Yen
Ananda‐Rajah, Michelle R.
Kidd, Sarah E.
Williams, Eloise
Chee, Lynette
Urbancic, Karen
Thursky, Karin A.
description Invasive fungal diseases (IFD) are serious infections associated with high mortality, particularly in immunocompromised patients. The prescribing of antifungal agents to prevent and treat IFD is associated with substantial economic burden on the health system, high rates of adverse drug reactions, significant drug–drug interactions and the emergence of antifungal resistance. As the population at risk of IFD continues to grow due to the increased burden of cancer and related factors, the need for hospitals to employ antifungal stewardship (AFS) programmes and measures to monitor and prevent infection has become increasingly important. These guidelines outline the essential components, key interventions and metrics, which can help guide implementation of an AFS programme in order to optimise antifungal prescribing and IFD management. Specific recommendations are provided for quality processes for the prevention of IFD in the setting of outbreaks, during hospital building works, and in the context of Candida auris infection. Recommendations are detailed for the implementation of IFD surveillance to enhance detection of outbreaks, evaluate infection prevention and prophylaxis interventions and to allow benchmarking between hospitals. Areas in which information is still lacking and further research is required are also highlighted.
doi_str_mv 10.1111/imj.15586
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2613289984</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2613289984</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3886-b22ca8715cccf7b86ce009f474a001e126d9c71038cb9e5e33e5fd8f034fced43</originalsourceid><addsrcrecordid>eNp10M1LwzAYBvAgipvTg_-AFLworFu-2iZHGX5MJl70JpQ2fTMz2nQm68b-e9ttehDMJe_hx8PDg9AlwSPSvrGpFiMSRSI-Qn3CeRRGUvLj3c1DLDHroTPvFxiThEl-inqMS5YQxvvoY1JbD9Y3Ppg3poDSWPCBrl2Q2ZXRjZ1nZeBXsMlc4T_Nchj4xq3BlGVmFbSoCIzVoFamtsHSwRpsdw4Diik5Ryc6Kz1cHP4Ben-4f5s8hbPXx-nkbhYqJkQc5pSqTCQkUkrpJBexAoyl5gnP2spAaFxIlRDMhMolRMAYRLoQGjOuFRScDdDNPnfp6q8G_CqtjFfQdYS68SmNCaNCStHR6z90UTfOtu06RXmMZUJbdbtXytXeO9Dp0pkqc9uU4LSbPG0nT3eTt_bqkNjkFRS_8mfjFoz3YGNK2P6flE5fnveR3yC7iu4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2612460972</pqid></control><display><type>article</type><title>Consensus guidelines for antifungal stewardship, surveillance and infection prevention, 2021</title><source>MEDLINE</source><source>Wiley Journals</source><creator>Khanina, Anna ; Tio, Shio Yen ; Ananda‐Rajah, Michelle R. ; Kidd, Sarah E. ; Williams, Eloise ; Chee, Lynette ; Urbancic, Karen ; Thursky, Karin A.</creator><creatorcontrib>Khanina, Anna ; Tio, Shio Yen ; Ananda‐Rajah, Michelle R. ; Kidd, Sarah E. ; Williams, Eloise ; Chee, Lynette ; Urbancic, Karen ; Thursky, Karin A. ; Australasian Antifungal Guidelines Steering Committee ; Australasian Antifungal Guidelines Steering Committee</creatorcontrib><description>Invasive fungal diseases (IFD) are serious infections associated with high mortality, particularly in immunocompromised patients. The prescribing of antifungal agents to prevent and treat IFD is associated with substantial economic burden on the health system, high rates of adverse drug reactions, significant drug–drug interactions and the emergence of antifungal resistance. As the population at risk of IFD continues to grow due to the increased burden of cancer and related factors, the need for hospitals to employ antifungal stewardship (AFS) programmes and measures to monitor and prevent infection has become increasingly important. These guidelines outline the essential components, key interventions and metrics, which can help guide implementation of an AFS programme in order to optimise antifungal prescribing and IFD management. Specific recommendations are provided for quality processes for the prevention of IFD in the setting of outbreaks, during hospital building works, and in the context of Candida auris infection. Recommendations are detailed for the implementation of IFD surveillance to enhance detection of outbreaks, evaluate infection prevention and prophylaxis interventions and to allow benchmarking between hospitals. Areas in which information is still lacking and further research is required are also highlighted.</description><identifier>ISSN: 1444-0903</identifier><identifier>EISSN: 1445-5994</identifier><identifier>DOI: 10.1111/imj.15586</identifier><identifier>PMID: 34937134</identifier><language>eng</language><publisher>Melbourne: John Wiley &amp; Sons Australia, Ltd</publisher><subject>Antifungal agents ; Antifungal Agents - therapeutic use ; antifungal stewardship ; Candidiasis, Invasive - drug therapy ; Candidiasis, Invasive - epidemiology ; Candidiasis, Invasive - prevention &amp; control ; Consensus ; Drug Resistance, Fungal ; hospital building work ; Hospitals ; Humans ; Immunocompromised Host ; Immunocompromised hosts ; infection prevention ; Infections ; invasive fungal disease ; Invasiveness ; outbreak management ; Outbreaks ; Prevention ; Prophylaxis ; quality process ; Surveillance</subject><ispartof>Internal medicine journal, 2021-11, Vol.51 (S7), p.18-36</ispartof><rights>2021 Royal Australasian College of Physicians.</rights><rights>2021 Royal Australasian College of Physicians</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3886-b22ca8715cccf7b86ce009f474a001e126d9c71038cb9e5e33e5fd8f034fced43</citedby><cites>FETCH-LOGICAL-c3886-b22ca8715cccf7b86ce009f474a001e126d9c71038cb9e5e33e5fd8f034fced43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fimj.15586$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fimj.15586$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34937134$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Khanina, Anna</creatorcontrib><creatorcontrib>Tio, Shio Yen</creatorcontrib><creatorcontrib>Ananda‐Rajah, Michelle R.</creatorcontrib><creatorcontrib>Kidd, Sarah E.</creatorcontrib><creatorcontrib>Williams, Eloise</creatorcontrib><creatorcontrib>Chee, Lynette</creatorcontrib><creatorcontrib>Urbancic, Karen</creatorcontrib><creatorcontrib>Thursky, Karin A.</creatorcontrib><creatorcontrib>Australasian Antifungal Guidelines Steering Committee</creatorcontrib><creatorcontrib>Australasian Antifungal Guidelines Steering Committee</creatorcontrib><title>Consensus guidelines for antifungal stewardship, surveillance and infection prevention, 2021</title><title>Internal medicine journal</title><addtitle>Intern Med J</addtitle><description>Invasive fungal diseases (IFD) are serious infections associated with high mortality, particularly in immunocompromised patients. The prescribing of antifungal agents to prevent and treat IFD is associated with substantial economic burden on the health system, high rates of adverse drug reactions, significant drug–drug interactions and the emergence of antifungal resistance. As the population at risk of IFD continues to grow due to the increased burden of cancer and related factors, the need for hospitals to employ antifungal stewardship (AFS) programmes and measures to monitor and prevent infection has become increasingly important. These guidelines outline the essential components, key interventions and metrics, which can help guide implementation of an AFS programme in order to optimise antifungal prescribing and IFD management. Specific recommendations are provided for quality processes for the prevention of IFD in the setting of outbreaks, during hospital building works, and in the context of Candida auris infection. Recommendations are detailed for the implementation of IFD surveillance to enhance detection of outbreaks, evaluate infection prevention and prophylaxis interventions and to allow benchmarking between hospitals. Areas in which information is still lacking and further research is required are also highlighted.</description><subject>Antifungal agents</subject><subject>Antifungal Agents - therapeutic use</subject><subject>antifungal stewardship</subject><subject>Candidiasis, Invasive - drug therapy</subject><subject>Candidiasis, Invasive - epidemiology</subject><subject>Candidiasis, Invasive - prevention &amp; control</subject><subject>Consensus</subject><subject>Drug Resistance, Fungal</subject><subject>hospital building work</subject><subject>Hospitals</subject><subject>Humans</subject><subject>Immunocompromised Host</subject><subject>Immunocompromised hosts</subject><subject>infection prevention</subject><subject>Infections</subject><subject>invasive fungal disease</subject><subject>Invasiveness</subject><subject>outbreak management</subject><subject>Outbreaks</subject><subject>Prevention</subject><subject>Prophylaxis</subject><subject>quality process</subject><subject>Surveillance</subject><issn>1444-0903</issn><issn>1445-5994</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp10M1LwzAYBvAgipvTg_-AFLworFu-2iZHGX5MJl70JpQ2fTMz2nQm68b-e9ttehDMJe_hx8PDg9AlwSPSvrGpFiMSRSI-Qn3CeRRGUvLj3c1DLDHroTPvFxiThEl-inqMS5YQxvvoY1JbD9Y3Ppg3poDSWPCBrl2Q2ZXRjZ1nZeBXsMlc4T_Nchj4xq3BlGVmFbSoCIzVoFamtsHSwRpsdw4Diik5Ryc6Kz1cHP4Ben-4f5s8hbPXx-nkbhYqJkQc5pSqTCQkUkrpJBexAoyl5gnP2spAaFxIlRDMhMolRMAYRLoQGjOuFRScDdDNPnfp6q8G_CqtjFfQdYS68SmNCaNCStHR6z90UTfOtu06RXmMZUJbdbtXytXeO9Dp0pkqc9uU4LSbPG0nT3eTt_bqkNjkFRS_8mfjFoz3YGNK2P6flE5fnveR3yC7iu4</recordid><startdate>202111</startdate><enddate>202111</enddate><creator>Khanina, Anna</creator><creator>Tio, Shio Yen</creator><creator>Ananda‐Rajah, Michelle R.</creator><creator>Kidd, Sarah E.</creator><creator>Williams, Eloise</creator><creator>Chee, Lynette</creator><creator>Urbancic, Karen</creator><creator>Thursky, Karin A.</creator><general>John Wiley &amp; Sons Australia, Ltd</general><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>202111</creationdate><title>Consensus guidelines for antifungal stewardship, surveillance and infection prevention, 2021</title><author>Khanina, Anna ; Tio, Shio Yen ; Ananda‐Rajah, Michelle R. ; Kidd, Sarah E. ; Williams, Eloise ; Chee, Lynette ; Urbancic, Karen ; Thursky, Karin A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3886-b22ca8715cccf7b86ce009f474a001e126d9c71038cb9e5e33e5fd8f034fced43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Antifungal agents</topic><topic>Antifungal Agents - therapeutic use</topic><topic>antifungal stewardship</topic><topic>Candidiasis, Invasive - drug therapy</topic><topic>Candidiasis, Invasive - epidemiology</topic><topic>Candidiasis, Invasive - prevention &amp; control</topic><topic>Consensus</topic><topic>Drug Resistance, Fungal</topic><topic>hospital building work</topic><topic>Hospitals</topic><topic>Humans</topic><topic>Immunocompromised Host</topic><topic>Immunocompromised hosts</topic><topic>infection prevention</topic><topic>Infections</topic><topic>invasive fungal disease</topic><topic>Invasiveness</topic><topic>outbreak management</topic><topic>Outbreaks</topic><topic>Prevention</topic><topic>Prophylaxis</topic><topic>quality process</topic><topic>Surveillance</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Khanina, Anna</creatorcontrib><creatorcontrib>Tio, Shio Yen</creatorcontrib><creatorcontrib>Ananda‐Rajah, Michelle R.</creatorcontrib><creatorcontrib>Kidd, Sarah E.</creatorcontrib><creatorcontrib>Williams, Eloise</creatorcontrib><creatorcontrib>Chee, Lynette</creatorcontrib><creatorcontrib>Urbancic, Karen</creatorcontrib><creatorcontrib>Thursky, Karin A.</creatorcontrib><creatorcontrib>Australasian Antifungal Guidelines Steering Committee</creatorcontrib><creatorcontrib>Australasian Antifungal Guidelines Steering Committee</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Internal medicine journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Khanina, Anna</au><au>Tio, Shio Yen</au><au>Ananda‐Rajah, Michelle R.</au><au>Kidd, Sarah E.</au><au>Williams, Eloise</au><au>Chee, Lynette</au><au>Urbancic, Karen</au><au>Thursky, Karin A.</au><aucorp>Australasian Antifungal Guidelines Steering Committee</aucorp><aucorp>Australasian Antifungal Guidelines Steering Committee</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Consensus guidelines for antifungal stewardship, surveillance and infection prevention, 2021</atitle><jtitle>Internal medicine journal</jtitle><addtitle>Intern Med J</addtitle><date>2021-11</date><risdate>2021</risdate><volume>51</volume><issue>S7</issue><spage>18</spage><epage>36</epage><pages>18-36</pages><issn>1444-0903</issn><eissn>1445-5994</eissn><abstract>Invasive fungal diseases (IFD) are serious infections associated with high mortality, particularly in immunocompromised patients. The prescribing of antifungal agents to prevent and treat IFD is associated with substantial economic burden on the health system, high rates of adverse drug reactions, significant drug–drug interactions and the emergence of antifungal resistance. As the population at risk of IFD continues to grow due to the increased burden of cancer and related factors, the need for hospitals to employ antifungal stewardship (AFS) programmes and measures to monitor and prevent infection has become increasingly important. These guidelines outline the essential components, key interventions and metrics, which can help guide implementation of an AFS programme in order to optimise antifungal prescribing and IFD management. Specific recommendations are provided for quality processes for the prevention of IFD in the setting of outbreaks, during hospital building works, and in the context of Candida auris infection. Recommendations are detailed for the implementation of IFD surveillance to enhance detection of outbreaks, evaluate infection prevention and prophylaxis interventions and to allow benchmarking between hospitals. Areas in which information is still lacking and further research is required are also highlighted.</abstract><cop>Melbourne</cop><pub>John Wiley &amp; Sons Australia, Ltd</pub><pmid>34937134</pmid><doi>10.1111/imj.15586</doi><tpages>19</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1444-0903
ispartof Internal medicine journal, 2021-11, Vol.51 (S7), p.18-36
issn 1444-0903
1445-5994
language eng
recordid cdi_proquest_miscellaneous_2613289984
source MEDLINE; Wiley Journals
subjects Antifungal agents
Antifungal Agents - therapeutic use
antifungal stewardship
Candidiasis, Invasive - drug therapy
Candidiasis, Invasive - epidemiology
Candidiasis, Invasive - prevention & control
Consensus
Drug Resistance, Fungal
hospital building work
Hospitals
Humans
Immunocompromised Host
Immunocompromised hosts
infection prevention
Infections
invasive fungal disease
Invasiveness
outbreak management
Outbreaks
Prevention
Prophylaxis
quality process
Surveillance
title Consensus guidelines for antifungal stewardship, surveillance and infection prevention, 2021
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T02%3A42%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Consensus%20guidelines%20for%20antifungal%20stewardship,%20surveillance%20and%20infection%20prevention,%202021&rft.jtitle=Internal%20medicine%20journal&rft.au=Khanina,%20Anna&rft.aucorp=Australasian%20Antifungal%20Guidelines%20Steering%20Committee&rft.date=2021-11&rft.volume=51&rft.issue=S7&rft.spage=18&rft.epage=36&rft.pages=18-36&rft.issn=1444-0903&rft.eissn=1445-5994&rft_id=info:doi/10.1111/imj.15586&rft_dat=%3Cproquest_cross%3E2613289984%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2612460972&rft_id=info:pmid/34937134&rfr_iscdi=true